Evox Therapeutics Overview
- Founded
- 2016

- Status
- Private
- Employees
- 108

- Latest Deal Type
- Series C
- Latest Deal Amount
- $95.4M

- Investors
- 12
Evox Therapeutics General Information
Description
Developer of exosome-based therapeutics designed to treat various severe diseases with profound implications for human health. The company's therapeutics use nucleic acid and protein delivery technology to harness and engineer the natural trafficking capabilities of extracellular vesicles, enabling healthcare providers to leverage proprietary targeting, manufacturing processes and purification methods.
Contact Information
- Oxford Science Park, Medawar Centre
- 2nd Floor East Building, Robert Robinson Avenue
- Oxford OX4 4HG
- England, United Kingdom
Evox Therapeutics Timeline
Evox Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series C) | 18-Feb-2021 | $95.4M | 00000 | Completed | Generating Revenue | |
3. Grant | 22-Mar-2019 | 00.000 | 000.00 | Completed | Generating Revenue | |
2. Early Stage VC (Series B) | 03-Sep-2018 | $45.6M | $60.2M | 000.00 | Completed | Generating Revenue |
1. Seed Round | 10-May-2016 | $14.6M | $14.6M | 0000 | Completed | Clinical Trials - Phase 1 |
Evox Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
A Preferred | 000,000 | 00.000000 | 00 | 0000.0 | 0000.0 | 00 | 0000.0 | 00.000 |
Ordinary | 000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
Evox Therapeutics Comparisons
Industry
000000 0
000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialEvox Therapeutics Competitors (16)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Kimera Labs | Corporation | Miramar, FL | 00 | 000000000 - | ||
000000 | Venture Capital-Backed | Seattle, WA | 00 | 000.00 | 0000000000 0 | 000.00 |
000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000 | 00000 |
000000 00000000000 | Venture Capital-Backed | Lexington, MA | 00 | 00000 | 00000000000 | 00000 |
00000000 | Venture Capital-Backed | Seattle, WA | 00 | 0000 | 000000000 - | 0000 |
Evox Therapeutics Executive Team (6)
Evox Therapeutics Board Members (14)
Name | Representing | Role | Since |
---|---|---|---|
Amrit Nagpal | Redmile Group | Board Member | 000 0000 |
Andrew McLean MD | Oxford Sciences Innovation | Board Member | 000 0000 |
Antonin de Fougerolles Ph.D | Evox Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
Chau Khuong | Self | Board Member | 000 0000 |
John McHutchison MD | Self | Board Member | 000 0000 |
Evox Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialEvox Therapeutics Investors (12)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
OrbiMed | PE/Buyout | Minority | 000 0000 | 000000 0 | |
The Invus Group | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Duchenne UK | Other | 000 0000 | 000000 0 | ||
Innovate UK | Government | 000 0000 | 000000 0 | ||
Bill & Melinda Gates Foundation | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 |